Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15863166 | 0.98 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2HSD11B1IDO1 | |
| SCHEMBL17761315 | 0.84 | SLC6A3 (0.62) | SLC6A3SLC6A4SLC6A2HSD11B1MAOA | |
| SCHEMBL17761293 | 0.81 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2HSD11B1MAOA | |
| SCHEMBL6500186 | 0.81 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2HSD11B1P2RX7 | |
| SCHEMBL6494941 | 0.80 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2HSD11B1P2RX7 | |
| SCHEMBL15863359 | 0.79 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2HSD11B1 | |
| SCHEMBL15862915 | 0.79 | HSD11B1 (0.41) | SLC6A3SLC6A4SLC6A2HSD11B1IDO1 | |
| SCHEMBL15862926 | 0.79 | HSD11B1 (0.41) | SLC6A3SLC6A4SLC6A2HSD11B1IDO1 | |
| SCHEMBL7899629 | 0.78 | SLC6A3 (0.96) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL15863088 | 0.78 | SLC6A3 (0.67) | SLC6A3SLC6A4SLC6A2HSD11B1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| WO-2014108406-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | TPMT, XDH, DPYD | SLC6A3 130/4885SLC6A4 359/4885SLC6A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.